Oral Oncology Reports最新文献

{"title":"Oral care interventions for the prevention and management of anticancer therapy–induced oral mucositis: A systematic review","authors":"Zahra Farivar ,&nbsp;Hamid Salehiniya ,&nbsp;Leili Alizadeh","doi":"10.1016/j.oor.2025.100759","DOIUrl":"10.1016/j.oor.2025.100759","url":null,"abstract":"<div><h3>Background</h3><div>Oral mucositis (OM) is a common and debilitating complication of cancer treatments, particularly chemotherapy and radiotherapy. It significantly impacts patients’ quality of life, increases healthcare costs, and can interrupt or delay cancer therapy. This systematic review aimed to evaluate the effectiveness of various oral care interventions in the prevention and management of OM in patients undergoing anticancer treatments.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted in PubMed, Web of Science, and Scopus databases, adhering to PRISMA guidelines. Eligible studies included clinical trials and cohort studies published between January 2000 and June 2025. The quality of included studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools.</div></div><div><h3>Results</h3><div>Out of 2542 records screened, 48 studies met the inclusion criteria. Among these, 16 studies evaluated professional oral health care (POHC), 16 assessed chlorhexidine rinses, 6 focused on patient education, 6 examined sodium bicarbonate rinses, and 4 studied saline rinses. POHC and patient education consistently demonstrated beneficial effects, with over 75 % of studies in these categories reporting significant reductions in OM incidence and severity. Chlorhexidine and saline rinses showed mixed or limited results: only 38 % of chlorhexidine studies and 25 % of saline studies reported a measurable benefit. Risk of bias was rated as low to moderate in most studies, with 14 studies rated as high quality.</div></div><div><h3>Conclusion</h3><div>This review highlights the effectiveness of structured oral care interventions particularly POHC and patient education in mitigating OM among cancer patients. These findings support the integration of evidence-based oral care protocols into routine oncology practice and emphasize the need for standardized clinical guidelines to enhance patient outcomes and quality of life.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"15 ","pages":"Article 100759"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144655715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing efficacy and safety of weekly vs. triweekly cisplatin concurrently with radiotherapy for locally advanced head and neck cancer: Systematic review and meta-analysis","authors":"Mohammed Amine Saâd ,&nbsp;Imad Taleb ,&nbsp;Sofia El Omri ,&nbsp;Hamadoun Traoré ,&nbsp;Imane Chahbounia ,&nbsp;Choukri Elm'hadi ,&nbsp;Saïda Lamine ,&nbsp;Mohammed Anouar Mokhlis ,&nbsp;Lamia Aalaoui ,&nbsp;Mohamed Reda Khmamouche ,&nbsp;Khaoula Alaoui Slimani ,&nbsp;Yassir Sbitti ,&nbsp;Tarik Mahfoud ,&nbsp;Hassan Errihani ,&nbsp;Mohamed Ichou ,&nbsp;Rachid Tanz","doi":"10.1016/j.oor.2025.100738","DOIUrl":"10.1016/j.oor.2025.100738","url":null,"abstract":"<div><h3>Background</h3><div>Cisplatin-based chemotherapy is widely used in the treatment of locally advanced head and neck cancer (HNC). The optimal dosing schedule, whether weekly or triweekly, has been a subject of debate. This study aims to evaluate the efficacy and safety of weekly versus triweekly cisplatin regimens in this patient population.</div></div><div><h3>Material and methods</h3><div>In accordance with the PRISMA guidelines, we conducted this meta-analysis to compare outcomes associated with weekly and triweekly cisplatin regimens. The endpoints examined were overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) and safety. This meta-analysis protocol was registered in PROSPERO (CRD42023461292).</div></div><div><h3>Results</h3><div>The analysis of survival outcomes demonstrated no difference between the two schedules in terms of OS, PFS, LRRFS and DMFS at 2 and 3 years and 5 years (except for 2 years LRRFS). The odds ratio of OS at 2 years was 1.02 (p = 0.87) at 3 years 0.90 (p = 0.46) and at 5 years 1.13 (p = 0.59), and for PFS at the OR 2 years was 0.97 (p = 0.85) at 3 years 0.87 (p = 0.30) and at 5 years 0.86 (p = 0.55). Triweekly was superior to weekly cisplatin in terms of short-term LRRFS (at 2 years), with an OR of 1.57 (p = 0.02). Both protocols were similar in terms of adverse events.</div></div><div><h3>Conclusion</h3><div>Both weekly and triweekly cisplatin regimens show comparable survival outcomes and safety profiles in patients with head and neck cancers, except for short term LRRFS (at 2 years). These findings suggest that treatment decisions should be tailored to the patient's individual profile, including comorbidities and tolerability. Future studies should explore cumulative dosing and biomarkers to refine treatment strategies further.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100738"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision-directed therapy in salivary duct carcinoma","authors":"Shambhavi Singh ,&nbsp;Irene George ,&nbsp;Darshana Patil ,&nbsp;Prashant Kumar ,&nbsp;Rajan Datar ,&nbsp;Vijay Haribhakti ,&nbsp;Aditya Shreenivas ,&nbsp;Sewanti Limaye","doi":"10.1016/j.oor.2025.100748","DOIUrl":"10.1016/j.oor.2025.100748","url":null,"abstract":"<div><div>Salivary ductal carcinoma is a rare, aggressive salivary gland carcinoma with poor prognosis and high relapse rate. In recurrent metastatic cases, the median survival is only 5 months. Despite the treatment with multimodal therapeutic strategies, conventional treatments demonstrate a limited effect on long-term survival of the patients. In this study we report two cases of salivary ductal carcinoma patients managed with precision-directed, biomarker-guided therapeutic approaches. In the first case androgen receptor (AR) and HER2 positivity by immunohistochemistry analysis were detected. The patient was treated with AR directed targeted therapy enzalutamide and Leuprolide as maintenance therapy. Disease progression with an emergent HER2 expression by immunohistochemistry led to the inclusion of trastuzumab and pertuzumab. While in the second case the patient progressed on neoadjuvant chemotherapy and the subsequent molecular analysis revealed high expression of PD-L1 and was treated with pembrolizumab in combination with chemotherapy. Follow up assessment revealed treatment durable responses and disease control in both the patients. These cases underscore the potential role of comprehensive molecular profiling-guided personalised therapeutic approaches in the management of advanced SDC patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100748"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swallowing function, body image and uncertainty in illness after reconstruction in oral cancer survivors","authors":"Chen-Chan Kuo ,&nbsp;Shiu-Yu C. Katie Lee ,&nbsp;Chun-Ta Liao","doi":"10.1016/j.oor.2025.100734","DOIUrl":"10.1016/j.oor.2025.100734","url":null,"abstract":"<div><h3>Background</h3><div>Swallowing and body image are the main concerns after reconstruction for oral cancer. Perceiving uncertainty or an unpredictable future is a significant psychosocial stressor in cancer survivors. This study aimed to explore swallowing function, body image, and uncertainty after the reconstruction for oral cancer, and to examine their associations.</div></div><div><h3>Methods</h3><div>A consecutive sample of 155 oral cancer adults (147 males and 8 females), with or without adjuvants, and surviving 3–30 months after primary microvascular free flaps, were included. The main outcomes were assessed by the Body Image Scale, EORTC QLQ-HN 35, and Mishel's Uncertainty in Illness Scale.</div></div><div><h3>Results</h3><div>Participants reported moderate disturbance in appearance, body as a whole, and sexual attraction, and a moderate-to-low level of EORTC swallowing, speech, and social problems. Less than 20 % have pursued cosmetic surgeries after reconstruction. After adjusting for demographic and clinical factors, poor body image (<em>β</em> = .318), poor speech (<em>β</em> = .198), lower household incomes (<em>β</em> = -.153), and farmers v.s. counterparts were more likely to have higher uncertainty in illness (Adj.R² = .347).</div></div><div><h3>Conclusions</h3><div>Along with body image disturbance and swallowing problems, financial burden or work-related stress are significant risk factors for higher uncertainty in illness. Providing supportive care to cope with body image disturbances, swallowing and speech problems, and to improve work or financial status are warranted to help oral cancer survivors to cope with uncertainty in illness after free flaps.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100734"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50 (Gy) in 20 study”","authors":"Efsun Somay ,&nbsp;Erkan Topkan ,&nbsp;Ugur Selek","doi":"10.1016/j.oor.2025.100739","DOIUrl":"10.1016/j.oor.2025.100739","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100739"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sinonasal primary squamous cell carcinoma: A case report to illustrate key diagnostic and therapeutic considerations in managing sinonasal squamous cell carcinoma","authors":"A.C. Drossaert ,&nbsp;G.K.P. Bittermann ,&nbsp;P.A.W.H. Kessler","doi":"10.1016/j.oor.2025.100736","DOIUrl":"10.1016/j.oor.2025.100736","url":null,"abstract":"<div><div>Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy that affects the nasal cavity and paranasal sinuses, representing only 3 % of nasopharyngeal malignancies. It predominantly affects the maxillary sinus, with less frequent involvement of the ethmoid and sphenoid sinuses. SNSCC typically presents with nonspecific symptoms such as epistaxis, pain, and signs of ulceration, often leading to a delayed diagnosis. Due to its late presentation, aggressive nature, and potential for recurrence, SNSCC presents significant challenges in diagnosis and management. A representative clinical case is described to emphasize the importance of a multidisciplinary approach regarding the diagnosis and treatment in managing SNSCC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100736"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Resection of a left carotid body tumor in a young female patient”","authors":"Lucas Alves da Mota Santana ,&nbsp;Lara Góis Floresta ,&nbsp;Rajiv Gandhi Gopalsamy ,&nbsp;Bernardo Ferreira Brasileiro ,&nbsp;Cleverson Luciano Trento ,&nbsp;Lysandro Pinto Borges","doi":"10.1016/j.oor.2025.100733","DOIUrl":"10.1016/j.oor.2025.100733","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100733"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of recurrent oral carcinoma cuniculatum with immune checkpoint blockade: A case report and literature review","authors":"William Jones ,&nbsp;Azeem S. Kaka ,&nbsp;Soumon Rudra ,&nbsp;Daniel Lubin ,&nbsp;Faisal Saeed ,&nbsp;Kelly R. Magliocca ,&nbsp;Nabil F. Saba ,&nbsp;Nicole C. Schmitt","doi":"10.1016/j.oor.2025.100746","DOIUrl":"10.1016/j.oor.2025.100746","url":null,"abstract":"<div><h3>Background</h3><div>Carcinoma cuniculatum (CC) is a rare variant of carcinoma that can arise in the oral cavity. CC can be locally aggressive but rarely metastasizes, and there are few reports of treatment with systemic therapy.</div></div><div><h3>Methods</h3><div>We present a case of a 44-year-old man with T4bN0 oral carcinoma cuniculatum of the retromolar trigone.</div></div><div><h3>Results</h3><div>Despite resection with wide margins and adjuvant radiation, the disease recurred 14 months later and was extensive. Following positive margins on a repeat resection, the patient opted for systemic therapy. Despite a PD-L1 combined positive score of 15, the patient did not respond to immunotherapy (pembrolizumab).</div></div><div><h3>Conclusion</h3><div>Though it has a low propensity for metastasis, oral CC is a locally aggressive variant of squamous cell carcinoma, and recurrences are difficult to treat. Although reports of systemic therapy for CC are limited, this case suggests that immunotherapy may have limited activity in this oral cancer variant.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100746"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Association between dental exams and diagnosis of head and neck cancer”","authors":"Palanivel Velmurugan,&nbsp;Vinayagam Mohanavel,&nbsp;Kanagasabapathy Sivasubramanian","doi":"10.1016/j.oor.2025.100747","DOIUrl":"10.1016/j.oor.2025.100747","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100747"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma","authors":"Anouk W.M.A. Schaeffers ,&nbsp;Hannah A. Scholten ,&nbsp;Annemieke Kok ,&nbsp;Floris C.J. Reinders ,&nbsp;Rebecca K. Stellato ,&nbsp;Ernst J. Smid ,&nbsp;Maartje A. van Beers ,&nbsp;Carla H. van Gils ,&nbsp;Caroline M. Speksnijder ,&nbsp;Marielle P. Philippens ,&nbsp;Lot A. Devriese ,&nbsp;Remco de Bree","doi":"10.1016/j.oor.2025.100737","DOIUrl":"10.1016/j.oor.2025.100737","url":null,"abstract":"<div><h3>Background and purpose</h3><div>The aim is to investigate whether lumbar skeletal muscle index (LSMI) decreases during treatment of head and neck squamous cell carcinoma (HNSCC) patients, and which pre-treatment variables are associated with change.</div></div><div><h3>Materials and methods</h3><div>The LSMI before and during treatment was assessed using MRI scans of HNSCC patients treated with radiotherapy (RT) or chemoradiotherapy (CRT). Mixed models assessed LSMI change and pre-treatment covariates (i.e. age, BMI, tumor characteristics and treatment type).</div></div><div><h3>Results</h3><div>In 63 patients the LSMI decreased from 40.56 cm²/m² to 39.96 cm²/m² (<em>p</em> trend = 0.008) on average. The LSMI of CRT patients decreased more than the LSMI of RT patients, but this was not significant (40.85–39.63 cm²/m² vs. 40.37 to 40.19 cm²/m²; p-interaction = 0.052). No effects of pre-treatment covariates on the LSMI trend over time were observed.</div></div><div><h3>Conclusion</h3><div>LSMI decreased during treatment in HNSCC patients, which was not related to pre-treatment variables, but seemed slightly larger for CRT patients than RT patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100737"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}